This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nielsen, G. P. Articles by Louis, D. N. Search for Related Content PubMed PubMed Citation Articles by Nielsen, G. P. Articles by Louis, D. N.

(American Journal of Pathology. 1999;155:1879-1884.)
© 1999 American Society for Investigative Pathology

Regular Articles

Malignant Transformation of Neurofibromas in Neurofibromatosis 1 Is Associated with CDKN2A/p16 Inactivation

Gunnlaugur P. Nielsen^*, Anat O. Stemmer-Rachamimov^*, Yasushi Ino^*, Michael B. Møller, Andrew E. Rosenberg^* and David N. Louis^*

From the Molecular Neuro-Oncology Laboratory and the James Homer Wright Pathology Laboratories,^*
Department of Pathology and Neurosurgical Service, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; and the Department of Pathology,
University of Southern Denmark, Odense University, Odense, Denmark

Patients with neurofibromatosis 1 (NF1) are predisposed to develop multiple neurofibromas (NFs) and are at risk for transformation of NFs to malignant peripheral nerve sheath tumors (MPNSTs). Little is known, however, about the biological events involved in the malignant transformation of NFs. We examined the CDKN2A/p16 gene and p16 protein in NFs and MPNSTs from patients with NF1. On immunohistochemical analysis, all NFs expressed p16 protein. The MPNSTs, however, were essentially immunonegative for p16, with striking transitions in cases that contained both benign and malignant elements. None of the benign tumors had CDKN2A/p16 deletions, whereas three of six MPNSTs appeared to have homozygous CDKN2A/p16 deletions. Methylation analysis and mutation analysis of CDKN2A/p16 in MPNSTs did not reveal any abnormalities. These results show that malignant transformation of NF is associated with loss of p16 expression, which is often secondary to homozygous deletion of the CDKN2A/p16 gene. The findings suggest that CDKN2A/p16 inactivation occurs during the malignant transformation of NFs in NF1 patients and raises the possibility that p16 immunohistochemistry may provide ancillary information in the distinction of NF from MPNST.

This article has been cited by other articles:

				F. Perrone, L. Da Riva, M. Orsenigo, M. Losa, G. Jocolle, C. Millefanti, E. Pastore, A. Gronchi, M. A. Pierotti, and S. Pilotti PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor Neuro Oncology, December 1, 2009; 11(6): 725 - 736. [Abstract] [Full Text] [PDF]

				H. R. Brekke, M. Kolberg, R. I. Skotheim, K. S. Hall, B. Bjerkehagen, B. Risberg, H. A. Domanski, N. Mandahl, K. Liestol, S. Smeland, et al. Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors Neuro Oncology, October 1, 2009; 11(5): 514 - 528. [Abstract] [Full Text] [PDF]

				D. CABIBI, M. ZERILLI, G. CARADONNA, L. SCHILLACI, B. BELMONTE, and V. RODOLICO Diagnostic and Prognostic Value of CD10 in Peripheral Nerve Sheath Tumors Anticancer Res, August 1, 2009; 29(8): 3149 - 3155. [Abstract] [Full Text] [PDF]

				P. Levy, H. Ripoche, I. Laurendeau, V. Lazar, N. Ortonne, B. Parfait, K. Leroy, J. Wechsler, I. Salmon, P. Wolkenstein, et al. Microarray-Based Identification of Tenascin C and Tenascin XB, Genes Possibly Involved in Tumorigenesis Associated with Neurofibromatosis Type 1 Clin. Cancer Res., January 15, 2007; 13(2): 398 - 407. [Abstract] [Full Text] [PDF]

				S. J. Miller, F. Rangwala, J. Williams, P. Ackerman, S. Kong, A. G. Jegga, S. Kaiser, B. J. Aronow, S. Frahm, L. Kluwe, et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res., March 1, 2006; 66(5): 2584 - 2591. [Abstract] [Full Text] [PDF]

				G. Yang, W. Khalaf, L. van de Locht, J. H. Jansen, M. Gao, M. A. Thompson, B. A. van der Reijden, D. H. Gutmann, R. Delwel, D. W. Clapp, et al. Transcriptional Repression of the Neurofibromatosis-1 Tumor Suppressor by the t(8;21) Fusion Protein Mol. Cell. Biol., July 15, 2005; 25(14): 5869 - 5879. [Abstract] [Full Text] [PDF]

				S. Berghmans, R. D. Murphey, E. Wienholds, D. Neuberg, J. L. Kutok, C. D. M. Fletcher, J. P. Morris, T. X. Liu, S. Schulte-Merker, J. P. Kanki, et al. tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors PNAS, January 11, 2005; 102(2): 407 - 412. [Abstract] [Full Text] [PDF]

				R S Bridge Jr, J A Bridge, J R Neff, S Naumann, P Althof, and L A Bruch Recurrent chromosomal imbalances and structurally abnormal breakpoints within complex karyotypes of malignant peripheral nerve sheath tumour and malignant triton tumour: a cytogenetic and molecular cytogenetic study J. Clin. Pathol., November 1, 2004; 57(11): 1172 - 1178. [Abstract] [Full Text] [PDF]

				R. I. Skotheim, A. Kallioniemi, B. Bjerkhagen, F. Mertens, H. R. Brekke, O. Monni, S. Mousses, N. Mandahl, G. Soeter, J. M. Nesland, et al. Topoisomerase-II{alpha} Is Upregulated in Malignant Peripheral Nerve Sheath Tumors and Associated With Clinical Outcome J. Clin. Oncol., December 15, 2003; 21(24): 4586 - 4591. [Abstract] [Full Text] [PDF]

				K. Tada, M. Kochi, H. Saya, J.-i. Kuratsu, S. Shiraishi, T. Kamiryo, N. Shinojima, and Y. Ushio Preliminary observations on genetic alterations in pilocytic astrocytomasassociated with neurofibromatosis 1 Neuro Oncology, October 1, 2003; 5(4): 228 - 234. [Abstract] [PDF]

				F. Perrone, S. Tabano, F. Colombo, G. Dagrada, S. Birindelli, A. Gronchi, M. Colecchia, M. A. Pierotti, and S. Pilotti p15INK4b, p14ARF, and p16INK4a Inactivation in Sporadic and Neurofibromatosis Type 1-related Malignant Peripheral Nerve Sheath Tumors Clin. Cancer Res., September 15, 2003; 9(11): 4132 - 4138. [Abstract] [Full Text] [PDF]

				R. P. H. Huijbregts, K. A. Roth, R. E. Schmidt, and S. L. Carroll Hypertrophic Neuropathies and Malignant Peripheral Nerve Sheath Tumors in Transgenic Mice Overexpressing Glial Growth Factor {beta}3 in Myelinating Schwann Cells J. Neurosci., August 13, 2003; 23(19): 7269 - 7280. [Abstract] [Full Text] [PDF]

				B. Govindarajan, M. C. Mizesko, M. S. Miller, H. Onda, M. Nunnelly, K. Casper, D. Brat, C. Cohen, and J. L Arbiser Tuberous Sclerosis-associated Neoplasms Express Activated p42/44 Mitogen-activated Protein (MAP) Kinase, and Inhibition of MAP Kinase Signaling Results in Decreased in Vivo Tumor Growth Clin. Cancer Res., August 1, 2003; 9(9): 3469 - 3475. [Abstract] [Full Text] [PDF]

				Plexiform neurofibromas in NF1: Toward biologic-based therapy Neurology, May 28, 2002; 58(10): 1461 - 1470.

				R. E. Ferner and D. H. Gutmann International Consensus Statement on Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis 1 Cancer Res., March 1, 2002; 62(5): 1573 - 1577. [Abstract] [Full Text] [PDF]

				J. Li, A. Perry, C. D. James, and D. H. Gutmann Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas Neurology, April 10, 2001; 56(7): 885 - 890. [Abstract] [Full Text] [PDF]